人腹水型卵巢癌SCID鼠腹腔移植瘤的建立  

Establishment of transplantable asictes tumor models of human ovarian cancinoma in SCID mice

作　　者：姚凤球[1] 凌斌[1] 赵卫东[1] 王群华[2] 周颖[1] 陈柯[1] 胡文[1] 

机构地区：[1]安徽医科大学附属省立医院妇产科,合肥230001 [2]中国福利会国际和平妇幼保健院妇产科,上海200030

出　　处：《安徽医科大学学报》2006年第2期124-126,共3页Acta Universitatis Medicinalis Anhui

基　　金：国家高技术研究发展计划(863计划)基金资助课题(编号:2002AA216151);安徽省自然科学基金资助项目(编号:03043703)

摘　　要：目的为研究人腹水型卵巢癌的实验研究提供合适的动物模型。方法将2例伴有大量腹水的卵巢癌患者手术切除标本移植于SCID鼠腹腔,原代移植瘤形成后进行鼠间传代,观察移植瘤的生长、转移及腹水形成情况,腹水细胞学涂片、计数,检测荷瘤鼠血和腹水中卵巢癌相关抗原CA125的浓度,肿瘤组织及器官作病理学检查。结果成功建立3只原代人卵巢癌SCID鼠腹水型移植瘤模型,原代移植成功率为37.5%,自第4代后,移植瘤的传代成功率为100%,随着传代次数的增加,移植瘤的成瘤潜伏期及荷瘤鼠的生存期均明显缩短(P<0.05),荷瘤鼠血和腹水中CA125的浓度升高,移植瘤仍保持原癌的病理形态特点。结论成功建立了人卵巢癌SCID鼠腹水型移植瘤模型,为研究人腹水型卵巢癌提供较理想的动物模型。Objective To establish transplantable ascites tumor models of human ovarian carcinoma in SCID mice, which will provide appropriate tumor models of human ovarian cancinoma for experimental study. Methods Two samples of human ovarian cancinoma with a lot of ascites were primary transplanted tumors were transplanted to SCID mice for peritoneally heterotransplanted to SCID mice. The six passages in turn. The volumes of tumor and ascites were observed , the concentration of tumor marker CA125 was screened, morphological characteristics of ascites,transplanted tumor and organs were studied with light microscopy. Results The model transplantable human ovarian carcioma producing ascites was established successfully, and the initial take rate was 37. 5%, then it increased to 100.0% after the fourth passage. With the increasement of passage, the latent periods of tumor growth and the mean survival time were shortened obviously. The concentration of tumor marker CA125 in blood and ascites of SCID mice also increased. The characteristics of histology was identical to those of human donor tumors. Conclusion The intraperitonally transplantable human ovarian cancinoma models have been established successfully. The models may become an ideal animal models for research of human ovarian cancinoma.

关 键 词：卵巢肿瘤 腹水 疾病模型 动物 肿瘤移植 小鼠 SCID 

分 类 号：R737.31[医药卫生—肿瘤] R73-352[医药卫生—临床医学]